Fasting levels of hepatic p-S6 are increased in old mice

Cell Cycle

Volumn 13, Issue 17, 2014, Pages 2656-2659

  Leontieva, Olga V ^a   Paszkiewicz, Geraldine M ^a   Blagosklonny, Mikhail V ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Aging; MTOR; Rapalogs; Rapamycin; Senescence

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN; PROTEIN KINASE B; PROTEIN S6; SOMATOMEDIN C; TARGET OF RAPAMYCIN KINASE;

ADULT; AGED; AGING; CALORIC RESTRICTION; CELL AGING; CELL CYCLE ARREST; CELL PROLIFERATION; DIET RESTRICTION; ENZYME ACTIVITY; EXERCISE; GROWTH STIMULATION; LIFE EXTENSION; LIFESPAN; LIVER LEVEL; MIDDLE AGED; MUSCLE HYPERTROPHY; NONHUMAN; PROTEIN CONTENT; PROTEIN SYNTHESIS; REVIEW; SARCOPENIA; SENESCENCE; YOUNG ADULT; ANIMAL; BODY WEIGHT; C57BL MOUSE; FEMALE; HEALTH; LIVER; LONGEVITY; METABOLISM; PHOSPHORYLATION;

AGING; ANIMALS; BODY WEIGHT; CELL AGING; FASTING; FEMALE; HEALTH; LIVER; LONGEVITY; MICE, INBRED C57BL; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; TOR SERINE-THREONINE KINASES;

EID: 84907588770     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/15384101.2014.949150     Document Type: Review

References (57)

1. Loewith R, Jacinto E, Wullschleger S, Lorberg A, Crespo JL, Bonenfant D, Oppliger W, Jenoe P, Hall MN. Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. Mol Cell 2002; 10:457-68; PMID: 12408816
2. Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev 2004; 18:1926-45; PMID: 15314020
3. Loewith R, Hall MN. Target of rapamycin (TOR) in nutrient signaling and growth control. Genetics 2011; 189:1177-1201; PMID:22174183; http://dx.doi.org/10.1534/genetics.111.133363
4. Sengupta S, Peterson TR, Sabatini DM. Regulation of the mTOR complex 1 pathway by nutrients, growth factors, and stress. Mol Cell 2010;40:310-322; PMID:20965424; http://dx.doi.org/10.1016/j.molcel.2010.09.026
5. Blagosklonny MV. Aging-suppressants: cellular senescence (hyperactivation) and its pharmacologic deceleration. Cell Cycle 2009;8:1883-1887; PMID: 19448395
6. Blagosklonny MV, Hall MN. Growth and aging: a common molecular mechanism. Aging 2009; 1:357-362; PMID:20157523
7. Dazert E, Hall MN. mTOR signaling in disease. Curr Opin Cell Biol 2011; 23(6):744-55; PMID:21963299;http://dx.doi.org/10.1016/j.ceb.2011.09.003
8. Blagosklonny MV. Prospective treatment of agerelated diseases by slowing down aging. Am J Pathol 2012;181: 1142-1146; PMID:22841821; http://dx.doi.org/10.1016/j.ajpath.2012.06.024
9. Kaeberlein M. Longevity and aging. F1000Prime Rep. 2013; 5:5; PMID:23513177; http://dx.doi.org/10.12703/P5-5
10. Johnson SC, Rabinovitch PS, Kaeberlein M. mTOR is a key modulator of ageing and age-related disease. Nature 2013;493:338-345; PMID:23325216; http://dx.doi.org/10.1038/nature11861
11. Harrison DE, Strong R, Sharp ZD, Nelson JF, Astle CM, Flurkey K, Nadon NL, Wilkinson JE, Frenkel K, Carter CS, et al. Rapamycin fed late in life extends lifespan in genetically heterogenous mice. Nature 2009;460:392-396; PMID:19587680; http://dx.doi.org/10.1038/nature08221
12. Miller RA, Harrison DE, Astle CM, Baur JA, Boyd AR, de Cabo R, Fernandez E, Flurkey K, Javors MA, Nelson JF, et al. Rapamycin, but not resveratrol or simvastatin, extends life span of genetically heterogeneous mice. J Gerontol A Biol Sci Med Sci 2011;66:191-201; PMID:20974732; http://dx.doi.org/10.1093/gerona/glq178
13. Anisimov VN, Zabezhinski MA, Popovich IG, Piskunova TS, Semenchenko AV, Tyndyk ML, Yurova MN, Rosenfeld SV, Blagosklonny MV. Rapamycin increases lifespan and inhibits spontaneous tumorigenesis in inbred female mice. Cell Cycle 2011;10:4230-4236; PMID:22107964; http://dx.doi.org/10.4161/cc.10.24.18486
14. Ramos FJ, Chen SC, Garelick MG, Dai DF, Liao CY, Schreiber KH, MacKay VL, An EH, Strong R, Ladiges WC, et al. Rapamycin reverses elevated mTORC1 signaling in lamin AC-deficient mice, rescues cardiac and skeletal muscle function, and extends survival. Sci Transl Med 2012;4:144ra103; PMID:22837538;http://dx.doi.org/10.1126/scitranslmed.3003802
15. FokWC, Chen Y, Bokov A, Zhang Y, Salmon AB, Diaz V, Javors M, Wood WH III, Zhang Y, Becker KG, et al. Mice fed rapamycin have an increase in lifespan associated with major changes in the liver transcriptome. PLoS One 2013;9:e83988; PMID:24409289; http://dx.doi.org/10.1371/journal.pone.0083988
16. Wilkinson JE, Burmeister L, Brooks SV, Chan CC, Friedline S, Harrison DE, Hejtmancik JF, Nadon N, Strong R, Wood LK, et al. Rapamycin slows aging in mice. Aging Cell 2012;11:675-82; PMID:22587563; http://dx.doi.org/10.1111/j.1474-9726.2012.00832.x
17. Spong A, Bartke A. Rapamycin slows aging in mice. Cell Cycle 2012;11. 845; PMID:22356747; http://dx.doi.org/10.4161/cc.11.5.19607
18. Miller RA, Harrison DE, Astle CM, Fernandez E, Flurkey K, Han M, Javors MA, Li X, Nadon NL, Nelson JF, et al. Rapamycin-mediated lifespan increase in mice is dose and sex-dependent and appears metabolically distinct from dietary restriction. Aging Cell 2013; 13(3):468-77; PMID:24341993;http://dx.doi.org/10.1111/acel.12194
19. Selman C, Partridge L. A double whammy for aging? Rapamycin extends lifespan and inhibits cancer in inbred female mice. Cell Cycle 2012;11:17-18; PMID:22186783; http://dx.doi.org/10.4161/cc.11.1.18736
20. Zhang Y, Bokov A, Gelfond J, Soto V, Ikeno Y, Hubbard G, Diaz V, Sloane L, Maslin K, Treaster S, et al. Rapamycin extends life and health in C57BL6 mice. J Gerontol A Biol Sci Med Sci 2014;69:119-130; PMID:23682161; http://dx.doi.org/10.1093/gerona/glt056
21. Popovich IG, Anisimov VN, Zabezhinski MA, Semenchenko AV, Tyndyk ML, Yurova MN, Blagosklonny MV. Lifespan extension and cancer prevention in HER-2neu transgenic mice treated with low intermittent doses of rapamycin. Cancer Biol Ther 2014;15:586-592; PMID:24556924;http://dx.doi.org/10.4161/cbt.28164
22. Blagosklonny MV. mTOR-driven aging: speeding car without brakes. Cell Cycle 2009;8:4055-4059; PMID:19923900
23. Hansen M, Taubert S, Crawford D, Libina N, Lee SJ, Kenyon C. Lifespan extension by conditions that inhibit translation in Caenorhabditis elegans. Aging Cell 2007;6:95-110; PMID:17266679
24. Pan KZ, Palter JE, Rogers AN, Olsen A, Chen D, Lithgow GJ, Kapahi P. Inhibition of mRNA translation extends lifespan in Caenorhabditis elegans. Aging Cell 2007;6:111-119; PMID:17266680
25. Kaeberlein M, Kennedy BK. Hot topics in aging research: protein translation and TOR signaling, 2010. Aging Cell 2011;10:185-90; PMID:21176090; http://dx.doi.org/10.1111/j.1474-9726.2010.00665.x
26. Mehta R, Chandler-Brown D, Ramos FJ, Shamieh LS, Kaeberlein M. Regulation of mRNA translation as a conserved mechanism of longevity control. Adv Exp Med Biol 2011;694:14-29; PMID:20886753
27. Pospelova TV, Demidenko ZN, Bukreeva EI, Pospelov VA, Gudkov AV, Blagosklonny MV. Pseudo-DNA damage response in senescent cells. Cell Cycle 2009;8:4112-8; PMID:19946210
28. Leontieva OV, Demidenko ZN, Blagosklonny MV. MEK drives cyclin D1 hyperelevation during geroconversion. Cell Death Diff. 2013;20:1241-9; PMID: 23852369; http://dx.doi.org/10.1038/cdd.2013.86
29. Leontieva OV, Blagosklonny MV. CDK46-inhibiting drug substitutes for p21 and p16 in senescence: duration of cell cycle arrest and MTOR activity determine geroconversion. Cell Cycle 2013;12:3063-9; PMID:23974099; http://dx.doi.org/10.4161/cc.26130
30. Leontieva OV, Blagosklonny MV. M(o)TOR of pseudo-hypoxic state in aging: rapamycin to the rescue. Cell Cycle 2014;13:(4):509-15; PMID:24496328; http://dx.doi.org/10.4161/cc.27973
31. Blagosklonny MV. Cell cycle arrest is not yet senescence, which is not just cell cycle arrest: terminology for TOR-driven aging. Aging (Albany NY) 2012;4:159-65; PMID:22394614
32. Cho S, Hwang ES. Status of mTOR activity may phenotypically differentiate senescence and quiescence. Mol Cells 2012;33:597-604; PMID:22570149; http://dx.doi.org/10.1007/s10059-012-0042-1
33. Demidenko ZN, Korotchkina LG, Gudkov AV, Blagosklonny MV. Paradoxical suppression of cellular senescence by p53. Proc Natl Acad Sci U S A 2010;107:9660-4; PMID:20457898; http://dx.doi.org/10.1073/pnas.1002298107
34. Leontieva OV, Natarajan V, Demidenko ZN, Burdelya LG, Gudkov AV, Blagosklonny MV. Hypoxia suppresses conversion from proliferative arrest to cellular senescence. Proc Natl Acad Sci U S A 2012;109:13314-8; PMID:22847439; http://dx.doi.org/10.1073/pnas.1205690109
35. Kolesnichenko M, Hong L, Liao R, Vogt PK, Sun P. Attenuation of TORC1 signaling delays replicative and oncogenic RAS-induced senescence. Cell Cycle 2012;11:2391-401; PMID:22627671; http://dx.doi.org/10.4161/cc.20683
36. Serrano M. Dissecting the role of mTOR complexes in cellular senescence. Cell Cycle 2012;11:2231-2; PMID:22714590; http://dx.doi.org/10.4161/cc.21065
37. Iglesias-Bartolome R, Patel V, Cotrim A, Leelahavanichkul K, Molinolo AA, Mitchell JB, Gutkind JS. mTOR inhibition prevents epithelial stem cell senescence and protects from radiation-induced mucositis. Cell Stem Cell 2012;11:401-14; PMID:22958932; http://dx.doi.org/10.1016/j.stem.2012.06.007
38. Dulic V. Senescence regulation by mTOR. Methods Mol Biol 2013;965:15-35; PMID:23296649; http://dx.doi.org/10.1007/978-1-62703-239-1-2
39. Leontieva OV, Demidenko ZN, Blagosklonny MV. Contact inhibition and high cell density deactivate the mammalian target of rapamycin pathway, thus suppressing the senescence program. Proc Natl Acad Sci U S A 2014; 111:8832-7; PMID:24889617; http://dx.doi.org/10.1073/pnas.1405723111
40. Hinojosa CA,Mgbemena V, Van Roekel S, Austad SN, Miller RA, Bose S, Orihuela CJ. Enteric-delivered rapamycin enhances resistance of aged mice to pneumococcal pneumonia through reduced cellular senescence. Exp Gerontol 2012;47:958-65; PMID:22981852; http://dx.doi.org/10.1016/j.exger.2012.08.013
41. Leontieva OV, Demidenko ZN, Blagosklonny MV. Rapamycin reverses insulin resistance (IR) in highglucose medium without causing IR in normoglycemic medium. Cell Death Dis 2014;5:e1214; PMID:24810050; http://dx.doi.org/10.1038/cddis.2014.178
42. Sengupta S, Peterson TR, Laplante M, Oh S, Sabatini DM. mTORC1 controls fasting-induced ketogenesis and its modulation by ageing. Nature 2010;468:1100-4; PMID:21179166; http://dx.doi.org/10.1038/nature09584
43. Speakman JR, Hambly C. Starving for life: what animal studies can and cannot tell us about the use of caloric restriction to prolong human lifespan. J Nutr 2007;137:1078-86; PMID:17374682
44. Stanfel MN, Shamieh LS, Kaeberlein M, Kennedy BK. The TOR pathway comes of age. Biochim Biophys Acta 2009;1790:1067-1074; PMID:19539012; http://dx.doi.org/10.1016/j.bbagen.2009.06.007
45. Blagosklonny MV. Calorie restriction: decelerating mTOR-driven aging from cells to organisms (including humans). Cell Cycle 2010;9:683-8; PMID:20139716
46. Mercken EM, Carboneau BA, Krzysik-Walker SM, de Cabo R. Of mice and men: the benefits of caloric restriction, exercise, and mimetics. Ageing Res Rev 2012;11:390-8; PMID:22210414; http://dx.doi.org/10.1016/j.arr.2011.11.005
47. Kaeberlein M, Kennedy BK. Ageing: a midlife longevity drug? Nature. 2009;460:331-2; PMID:19606132; http://dx.doi.org/10.1038/460331a
48. Cava E, Fontana L. Will calorie restriction work in humans? Aging (Albany NY) 2013; 5:507-14; PMID:23924667
49. Emran S, Yang M, He X, Zandveld J, Piper MD. Target of rapamycin signaling mediates the lifespanextending effects of dietary restriction by essential amino acid alteration. Aging (Albany NY) 2014; 6:390-8; PMID:24861087
50. Weindruch R, Walford RL. Dietary restriction in mice beginning at 1 year of age: effect on life-span and spontaneous cancer incidence. Science 1982;215:1415-8;PMID:7063854
51. Levine ME, Suarez JA, Brandhorst S, Balasubramanian P, Cheng CW, Madia F, Fontana L, Mirisola MG, Guevara-Aguirre J, Wan J, et al. Low protein intake is associated with a major reduction in IGF-1, cancer, and overall mortality in the 65 and younger but not older population. Cell Metab 2014;19:407-17; PMID:24606898; http://dx.doi.org/10.1016/j.cmet.2014.02.006
52. Chen C, Liu Y, Zheng P. mTOR regulation and therapeutic rejuvenation of aging hematopoietic stem cells. Sci Signal 2009;2:ra75; PMID:19934433; http://dx.doi.org/10.1126/scisignal.2000559
53. Fry CS, Drummond MJ, Glynn EL, Dickinson JM, Gundermann DM, Timmerman KL, Walker DK, Dhanani S, Volpi E, Rasmussen BB. Aging impairs contraction-induced human skeletal muscle mTORC1 signaling and protein synthesis. Skelet Muscle 2011;1:11; PMID:21798089; http://dx.doi.org/10.1186/2044-5040-1-11
54. D'Antona G, Nisoli E. mTOR signaling as a target of amino acid treatment of the age-related sarcopenia. Interdiscip Top Gerontol 2010;37:115-41; PMID:20703059; http://dx.doi.org/10.1159/000319998
55. Sandri M, Barberi L, Bijlsma AY, Blaauw B, Dyar KA, Milan G, Mammucari C, Meskers CG, Pallafacchina G, Paoli A, et al. Signalling pathways regulating muscle mass in ageing skeletal muscle: the role of the IGF1-Akt-mTOR-FoxO pathway. Biogerontology 2014;14:303-23; PMID:23686362; http://dx.doi.org/10.1007/s10522-013-9432-9
56. Leontieva OV, Paszkiewicz GM, Blagosklonny MV. Mechanistic or mammalian target of rapamycin (mTOR) may determine robustness in young male mice at the cost of accelerated aging. Aging (Albany NY) 2012;4:899-916; PMID:23443503
57. Leontieva OV, Paszkiewicz GM, Blagosklonny MV. Weekly administration of rapamycin improves survival and biomarkers in obese male mice on high-fat diet. Aging Cell 2014 Mar 22; 13(4):616-22; PMID:24655348; http://dx.doi.org/10.1111/acel.12211.